• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分组生存数据研究的样本量计算。

Sample size calculation for studies with grouped survival data.

机构信息

Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.

出版信息

Stat Med. 2018 Nov 30;37(27):3904-3917. doi: 10.1002/sim.7847. Epub 2018 Jun 10.

DOI:10.1002/sim.7847
PMID:29888484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6262878/
Abstract

Grouped survival data arise often in studies where the disease status is assessed at regular visits to clinic. The time to the event of interest can only be determined to be between two adjacent visits or is right censored at one visit. In data analysis, replacing the survival time with the endpoint or midpoint of the grouping interval leads to biased estimators of the effect size in group comparisons. Prentice and Gloeckler developed a maximum likelihood estimator for the proportional hazards model with grouped survival data and the method has been widely applied. Previous work on sample size calculation for designing studies with grouped data is based on either the exponential distribution assumption or the approximation of variance under the alternative with variance under the null. Motivated by studies in HIV trials, cancer trials and in vitro experiments to study drug toxicity, we develop a sample size formula for studies with grouped survival endpoints that use the method of Prentice and Gloeckler for comparing two arms under the proportional hazards assumption. We do not impose any distributional assumptions, nor do we use any approximation of variance of the test statistic. The sample size formula only requires estimates of the hazard ratio and survival probabilities of the event time of interest and the censoring time at the endpoints of the grouping intervals for one of the two arms. The formula is shown to perform well in a simulation study and its application is illustrated in the three motivating examples.

摘要

分组生存数据在研究中经常出现,其中疾病状态在定期就诊时进行评估。感兴趣事件的时间只能确定为两次相邻就诊之间,或者在一次就诊时被右删失。在数据分析中,用分组区间的终点或中点替换生存时间会导致组间比较的效应大小的有偏估计。Prentice 和 Gloeckler 为分组生存数据的比例风险模型开发了一个最大似然估计器,该方法已被广泛应用。以前关于分组数据研究设计的样本量计算的工作是基于指数分布假设或替代假设下的方差近似,而不是基于零假设下的方差。受 HIV 试验、癌症试验和体外实验研究药物毒性的启发,我们为分组生存终点的研究开发了一个样本量公式,该公式使用 Prentice 和 Gloeckler 方法在比例风险假设下比较两个臂。我们不施加任何分布假设,也不使用检验统计量方差的任何近似值。样本量公式仅需要两个臂之一的感兴趣事件时间和分组区间终点的删失时间的危险比和生存概率的估计值。该公式在模拟研究中表现良好,并且在三个动机示例中说明了其应用。

相似文献

1
Sample size calculation for studies with grouped survival data.分组生存数据研究的样本量计算。
Stat Med. 2018 Nov 30;37(27):3904-3917. doi: 10.1002/sim.7847. Epub 2018 Jun 10.
2
Semiparametric analysis of survival data with left truncation and dependent right censoring.具有左截断和相依右删失的生存数据的半参数分析
Biometrics. 2005 Jun;61(2):567-75. doi: 10.1111/j.1541-0420.2005.00335.x.
3
Sample size calculation for the proportional hazards cure model.比例风险治愈模型的样本量计算。
Stat Med. 2012 Dec 20;31(29):3959-71. doi: 10.1002/sim.5465. Epub 2012 Jul 11.
4
Validity and efficiency of approximation methods for tied survival times in Cox regression.Cox回归中截尾生存时间近似方法的有效性和效率。
Biometrics. 1997 Sep;53(3):1151-6.
5
A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.比例风险治愈模型下加权对数秩检验的一种新型样本量公式。
Pharm Stat. 2017 Jan;16(1):87-94. doi: 10.1002/pst.1790. Epub 2016 Nov 8.
6
Subgroup detection and sample size calculation with proportional hazards regression for survival data.使用比例风险回归对生存数据进行亚组检测和样本量计算。
Stat Med. 2017 Dec 20;36(29):4646-4659. doi: 10.1002/sim.7441. Epub 2017 Aug 8.
7
Estimating the survival functions for right-censored and interval-censored data with piecewise constant hazard functions.用分段常数风险函数估计右删失和区间删失数据的生存函数。
Contemp Clin Trials. 2013 Jul;35(2):122-7. doi: 10.1016/j.cct.2013.04.009. Epub 2013 May 9.
8
Sample size planning of two-arm superiority and noninferiority survival studies with discrete follow-up.
Stat Med. 2017 Sep 10;36(20):3123-3136. doi: 10.1002/sim.7360. Epub 2017 Jun 12.
9
Power calculation for a score test in the dependent censoring model.相依删失模型中得分检验的功效计算。
Stat Med. 1996 May 30;15(10):1049-58. doi: 10.1002/(SICI)1097-0258(19960530)15:10<1049::AID-SIM216>3.0.CO;2-C.
10
Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules.存在不同访视计划时,带有分量级删失的复合终点分析。
Stat Med. 2022 Apr 30;41(9):1599-1612. doi: 10.1002/sim.9312. Epub 2022 Jan 18.

引用本文的文献

1
Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis.新型冠状病毒感染后静脉血栓栓塞事件的风险:系统评价和荟萃分析。
J Thromb Thrombolysis. 2023 Apr;55(3):490-498. doi: 10.1007/s11239-022-02766-7. Epub 2023 Jan 18.

本文引用的文献

1
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).晚期 IIIB/IV 期非小细胞肺癌初始铂类联合化疗后使用舒尼替尼维持治疗:一项随机、双盲、安慰剂对照的 III 期研究——CALGB 30607(联盟)
J Thorac Oncol. 2017 May;12(5):843-849. doi: 10.1016/j.jtho.2017.01.022. Epub 2017 Feb 1.
2
Sample size calculation in cost-effectiveness cluster randomized trials: optimal and maximin approaches.成本效益整群随机试验中的样本量计算:最优方法和极大极小方法
Stat Med. 2014 Jul 10;33(15):2538-53. doi: 10.1002/sim.6112.
3
Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model.
链式二项模型下离散或分组时间事件数据的 Mantel-Haenszel 检验及其他检验的功效。
Stat Med. 2013 Jan 30;32(2):220-9. doi: 10.1002/sim.5480. Epub 2012 Jul 16.
4
Misspecification of Cox regression models with composite endpoints.复合终点的 Cox 回归模型的误指定。
Stat Med. 2012 Dec 10;31(28):3545-62. doi: 10.1002/sim.5436. Epub 2012 Jun 27.
5
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.全基因组研究鉴定出细胞对紫杉醇敏感性的溶质载体转运蛋白。
Pharmacogenet Genomics. 2012 Jul;22(7):498-507. doi: 10.1097/FPC.0b013e328352f436.
6
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.无进展生存期和至疾病进展时间作为晚期乳腺癌的主要终点:常被使用,有时定义不严谨。
Ann Oncol. 2009 Mar;20(3):460-4. doi: 10.1093/annonc/mdn670. Epub 2008 Dec 18.
7
Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.病例队列研究中分组生存数据的加权似然法及其在HIV疫苗试验中的应用
Biometrics. 2008 Dec;64(4):1247-55. doi: 10.1111/j.1541-0420.2008.00998.x.
8
Endpoints for assessing drug activity in clinical trials.评估临床试验中药物活性的终点指标。
Oncologist. 2008;13 Suppl 2:19-21. doi: 10.1634/theoncologist.13-S2-19.
9
When you look matters: the effect of assessment schedule on progression-free survival.评估时间的重要性:评估时间表对无进展生存期的影响。
J Natl Cancer Inst. 2007 Mar 21;99(6):428-32. doi: 10.1093/jnci/djk091.
10
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.一项用于预防HIV-1感染的重组糖蛋白120疫苗的安慰剂对照3期试验。
J Infect Dis. 2005 Mar 1;191(5):654-65. doi: 10.1086/428404. Epub 2005 Jan 27.